Recommended

GSK appoints new CEO
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

USP General Chapter <660>—Glass revised

3
SHARES

To create opportunity for glass innovation, the Packaging and Distribution Expert Committee (PD EC) revised the United States Pharmacopeia (USP) General Chapter <660>—Glass.

USP General Chapter —Glass revised - container packaging

In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

On 1 October 2023, the final, official version of the chapter was published.

Glass container manufacturing

This change follows the USP’s Compendial Notice from January 2023, in which the PD EC announced that it intended to revise the General Chapter. The US Food and Drug Administration (FDA) had, in November 2022, requested revision of the Type 1 definition of glass in General Chapter <660>.

The FDA’s letter recommended that glass be “defined by its performance characteristics and not solely on its composition [to] allow for innovation in the manufacturing of glass intended for parenteral packaging.” In the document, it was reasoned that global shortage of these vials threatened the delivery of COVID-19 vaccines and availability of existing parenteral products.

PDA revises report on glass container manufacturing

Another USP Compendial Notice from January 2023 highlighted a need to use appropriate language in several of its monographs to support manufacturing flexibility of parenteral products. It noted that there are “about 380 USP monographs for parenteral products… [and] about 330 monographs that prescribe a specific type(s) of glass in the Packaging and storage section”.

Therefore, in February 2023, the organisation proposed that the compendial revisions include the term ‘preferably’ in relation to how these products are packaged. For example:

  • Preserve in single-dose containers, preferably of Type I glass
  • Preserve in single-dose or in multiple-dose containers, preferably of Type I or Type II glass.

According to USP, having been accelerated to create opportunity for glass innovation, the revision including different compositions beyond borosilicate and soda-lime-silica.

The PD EC plans to publish another major revision to <660> to modernise the testing procedures in the chapter, USP stated.

Europe’s pharmaceutical packaging market to value over $35bn by 2028

Share via
Share via